Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press7810.17650/1726-9776-2012-8-1-31-35DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиTHE SPECIFIC FEATURES OF A RESPONSE TO A TYROSINE KINASE INHIBITOR AGAINST DIFFERENT HISTOLOGICAL TYPES OF KIDNEY CANCER (A REVIEW)ОСОБЕННОСТИ ОТВЕТА НА ИНГИБИТОР ТИРОЗИНКИНАЗЫ РАЗЛИЧНЫХ ГИСТОЛОГИЧЕСКИХ ТИПОВ РАКА ПОЧКИ (ОБЗОР)KaprinA. D.КапринА. Д.
Russian Federation

Department of Urology with a Course of Oncourology

Кафедра урологии с курсом онкоурологии

andocrey@mail.ruKostinA. A.КостинА. А.
Russian Federation

Department of Urology with a Course of Oncourology

Кафедра урологии с курсом онкоурологии

andocrey@mail.ruAlekseevV. V.АлексеевВ. В.
Russian Federation

Department of Urology with a Course of Oncourology

Кафедра урологии с курсом онкоурологии

andocrey@mail.ruVarakinaA. Yu.ВаракинаА. Ю.
Russian Federation

Department of Urology with a Course of Oncourology

Кафедра урологии с курсом онкоурологии

andocrey@mail.ruPeople’s Friendship University of Russia, MoscowФПК МР РУДН, Москва300320128131352607201426072014https://oncourology.abvpress.ru/oncur/article/view/78

The paper deals with the results of a clinical trial covering patients with disseminated renal cell carcinoma of different histological types, who had no benefits from previous systemic therapy. The response of different histological types of kidney cancer to therapy with tyrosine kinase inhibitors, to sorafenib in particular, was studied within the trial. The findings strongly suggest that mainly patients with clear-cell renal cell carcinoma could achieve complete or partial remission.

Статья посвящена результатам клинического исследования пациентов с распространенным почечно-клеточным раком различных гистологических типов, у которых предшествующая системная терапия не дала результата. В рамках исследования изучался ответ различных гистологических типов рака почки на терапию ингибиторами тирозинкиназы, в частности на сорафениб. Как убедительно показывают полученные данные, полной или частичной ремиссии удалось добиться в основном у пациентов со светлоклеточным вариантом почечно-клеточного рака.

renal cell carcinomatyrosine kinase inhibitorsпочечно-клеточный ракингибиторы тирозинкиназы1. Chowdhury S., Choueiri T.K. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther 2009;9(3):373−9.Chowdhury S., Choueiri T.K. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther 2009;9(3):373−9.2. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312−8.Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312−8.3. Choueiri T.K., Plantade A., Elson P. et al. Efficacy of sunitinib and sorafenib in metastatic papilarry and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127−31.Choueiri T.K., Plantade A., Elson P. et al. Efficacy of sunitinib and sorafenib in metastatic papilarry and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127−31.4. Porta C., Bracarda J., Beck J. et al. Efficacy and safety of sorafenib in elderly patients: results from a large open-label, non-comparative phase III study in European patients with advanced RCC (EU-ARCCS). Ann Oncol 2008;19 (suppl 8):193.Porta C., Bracarda J., Beck J. et al. Efficacy and safety of sorafenib in elderly patients: results from a large open-label, non-comparative phase III study in European patients with advanced RCC (EU-ARCCS). Ann Oncol 2008;19 (suppl 8):193.5. Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral … in tumor progression and angiogenesis. Cancer Res 2004;64:7099−109 .Wilhelm S.M., Carter C., Tang L. et al. BAY 43-9006 exhibits broad spectrum oral … in tumor progression and angiogenesis. Cancer Res 2004;64:7099−109 .6. Avila M.A., Berasain C., Sangro B., Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25:3866−84.Avila M.A., Berasain C., Sangro B., Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25:3866−84.7. Liu L., Cao Y., Chen C. et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851–8.Liu L., Cao Y., Chen C. et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851–8.8. Semela D., Dufour J.F. et al. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864−80.Semela D., Dufour J.F. et al. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864−80.9. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312−8.Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312−8.10. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356:125−34.Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356:125−34.